Rivive Spray
NDC Package 82954-0100-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Rivive (naloxone hydrochloride) sprays is step 1: CHECK if you suspect an overdose•CHECK for a suspected overdose: the person will not wake up or is very sleepy or not breathing well•Yell “Wake up!”•Shake the person gently•If the person is not awake, go to Step 2Step 2: GIVE 1st dose in the nose•Hold nasal spray device with thumb on plunger and a finger on each side of the nozzle•Insert nozzle into one nostril and press plunger firmly•Each nasal spray device contains only one dose of naloxoneStep 3: CALL 911•Get medical help immediately after giving the first dose•Call 911 nowStep 4: WATCH & GIVE•WAIT 2-3 minutes after the 1st dose to give the medicine time to work•If the person wakes up: Go to Step 5•If the person does not wake up:• Give a second dose of medicine using a new nasal   spray device• It is safe to keep giving doses every 2-3 minutes until   the person wakes upStep 5: STAY•STAY until ambulance arrives: even if the person wakes up•GIVE another dose if the person becomes very sleepy again•You may need to give all the doses in the pack. This formulation utilizes a spray delivery system. Marketed by Harm Reduction Therapeutics, Inc., this product is identified by NDC 82954-0100 and is authorized under FDA application NDA217722.

Identification & Billing

NDC Package Code
82954-0100-1
Package Description
2 VIAL, SINGLE-DOSE in 1 CARTON / .1 mL in 1 VIAL, SINGLE-DOSE
Product Code
82954-0100
11-Digit Billing Format
82954010001
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Rivive
Non-Proprietary Name
Naloxone Hydrochloride
Substance Name
Naloxone Hydrochloride
Dosage Form
Spray - A liquid minutely divided as by a jet of air or steam.
Administration Route
Nasal - Administration to the nose; administered by way of the nose.
Active Ingredient(s)
NALOXONE HYDROCHLORIDE 3 mg/.1mL
Pharmacologic Class
Usage Information
Step 1: CHECK if you suspect an overdose•CHECK for a suspected overdose: the person will not wake up or is very sleepy or not breathing well•Yell “Wake up!”•Shake the person gently•If the person is not awake, go to Step 2Step 2: GIVE 1st dose in the nose•Hold nasal spray device with thumb on plunger and a finger on each side of the nozzle•Insert nozzle into one nostril and press plunger firmly•Each nasal spray device contains only one dose of naloxoneStep 3: CALL 911•Get medical help immediately after giving the first dose•Call 911 nowStep 4: WATCH & GIVE•WAIT 2-3 minutes after the 1st dose to give the medicine time to work•If the person wakes up: Go to Step 5•If the person does not wake up:• Give a second dose of medicine using a new nasal   spray device• It is safe to keep giving doses every 2-3 minutes until   the person wakes upStep 5: STAY•STAY until ambulance arrives: even if the person wakes up•GIVE another dose if the person becomes very sleepy again•You may need to give all the doses in the pack

Regulatory & Marketing

Labeler Name
Harm Reduction Therapeutics, Inc.
Product Type
Human Otc Drug
FDA Application #
NDA217722
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-02-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 82954-0100-1 identifies a specific commercial package of 2 vial, single-dose in 1 carton / .1 ml in 1 vial, single-dose of Rivive, a human over the counter drug labeled by Harm Reduction Therapeutics, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This spray is formulated for nasal use and contains naloxone hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Harm Reduction Therapeutics, Inc. on January 02, 2024. The current certification is valid through December 31, 2027.

How is this Harm Reduction Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 82954010001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
82954-0100-1
11-Digit CMS (5-4-2)
82954-0100-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.